New efficacy and safety data from 18-months of continued treatment with subcutaneous doses of SerpinPC…
– New clinical results from ongoing MGTA-117 Phase 1/2 clinical trial support earlier observations of…
Media Release Copenhagen, Denmark, November 3, 2022 Nineteen abstracts accepted, including multiple presentations on the…
New data from clinical trials of TT11 and TT11X to be featured in two oral…
– Oral presentation of MGTA-117 Phase 1/2 dose escalation clinical trial abstract, with additional clinical…
–Results from compassionate use program highlight promising activity of STRO-002 in children with rare form…
Interim data from phase III HAVEN 7 study reinforce Hemlibra’s efficacy and safety in infants…
Step Pharma to Present Promising Data on the Therapeutic Potential of Selective Small Molecule Inhibition…
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals,…
LEXINGTON, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a…
Abstract featuring updated data from KOMET-001 trial of ziftomenib accepted for oral presentation on December…
Nurix to provide a clinical update from the ongoing Phase 1 trial of NX-2127 in…
Clinical Presentations to Include Initial Clinical Data of FT576 BCMA-targeted CAR NK Cell Product Candidate…
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) — Imago BioSciences, Inc. (“Imago”) (Nasdaq:…
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX…
– Long-term Data for PYRUKYND® (mitapivat) in Adults with Pyruvate Kinase (PK) Deficiency and Adults…
BRISBANE, CALIFORNIA, Nov. 03, 2022 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company” or “GTB”)…
SAN FRANCISCO, Nov. 03, 2022 (GLOBE NEWSWIRE) — AltruBio Inc. (“AltruBio” or “the Company”), a…
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V. (Nasdaq: LVTX),…
Company to host conference call to discuss financial results and provide a corporate update on…